Teladoc Health (TDOC) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Teladoc Health (TDOC) right now is Integrated Care and chronic-condition management: Integrated Care is Teladoc's enterprise backbone, bundling general medical visits, mental-health access, and chronic-care programs for diabetes and hypertension carried over from Livongo. Revenue (FY2025) is ~$2,530 million, down ~2% from ~$2,570 million in 2024. If that keeps playing out, the setup is favourable; the risk to it is revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. No one can predict where TDOC trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Teladoc Health (TDOC) higher?
Integrated Care and chronic-condition management
Integrated Care is Teladoc's enterprise backbone, bundling general medical visits, mental-health access, and chronic-care programs for diabetes and hypertension carried over from Livongo. It grew modestly (about ~2% in Q1 2026 to roughly ~$395 million) and carries the company's healthier margins. Continued cross-selling of chronic-care and whole-person programs into existing employer and health-plan clients is the most-cited path to stabilizing total revenue.
Free cash flow and balance-sheet discipline
Management has reoriented the company around adjusted EBITDA and free cash flow rather than top-line growth. Full-year 2025 adjusted EBITDA landed in the roughly ~$270 to ~$287 million guidance range, and 2026 guidance points to free cash flow of about ~$130 to ~$170 million. Sustained cash generation is what supports debt paydown and gives the turnaround room to play out.
BetterHelp's shift toward insurance
BetterHelp's pure direct-to-consumer model has been squeezed by higher customer-acquisition costs and falling paying users. Teladoc is moving BetterHelp toward insurance-reimbursed therapy, guiding to roughly ~$90 to ~$105 million of BetterHelp insurance revenue in 2026 with a Q4 exit run-rate of at least about ~$125 million. Whether that channel can offset the consumer decline is a central open question.
AI and scale in virtual care
As the first and largest US telehealth platform, Teladoc has scale in clinician network, data, and employer relationships, and it markets AI and analytics tools for triage, documentation, and care navigation. Embedding AI to lower the cost per visit and improve outcomes is a stated lever, though it is early and competitors are pursuing similar automation.
What could weigh on TDOC?
Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of roughly ~$64 million in Q1 2026) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care.
How to think about a TDOC forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TDOC guide and whether TDOC is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TDOC outlook
The bottom line: what is driving Teladoc Health (TDOC) is Integrated Care and chronic-condition management, with revenue (fy2025) at ~$2,530 million, down ~2% from ~$2,570 million in 2024. If that keeps playing out the setup is favourable; the risk is revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. No one can predict the price, so treat any TDOC forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TDOC with Walnut
Use Teladoc Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Teladoc Health (TDOC)?
+
No one can reliably predict where TDOC will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Teladoc Health higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TDOC higher?
+
The main growth drivers are Integrated Care and chronic-condition management; Free cash flow and balance-sheet discipline; BetterHelp's shift toward insurance. Whether they play out is the real question, not a guaranteed path.
What are the risks to TDOC?
+
Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of roughly ~$64 million in Q1 2026) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care.
Will TDOC stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Teladoc Health's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TDOC a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TDOC "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.